Head-to-head evidence
Olanzapine (TV-44749) vs Paliperidone palmitate (Invega Sustenna)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Olanzapine (TV-44749)
Developed by Teva Pharmaceutical Industries
NCT05693935 · Phase 3 · completed
The 675-participant study was randomized, quadruple-blind, and placebo-controlled, with approximately 165 to 169 participants per blinded treatment group. Its primary clinical endpoint, change in PANSS total score at week 8, was significantly better with each TV-44749 dose than with placebo (all adjusted p<0.0001), supporting a strong evidence rating for the blinded efficacy comparison.
Paliperidone palmitate (Invega Sustenna)
Marketed by Johnson & Johnson
NCT00101634 · Phase 3 · completed
The study was randomized and double-blind, with 518 participants and a placebo comparison, and used a clinical symptom measure (change in total PANSS score) as its primary endpoint. Because no results are posted, it is not possible to determine whether the primary endpoint was met.
Next expected readout: December 2026 · NCT07493551 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (TV-44749)'s landscape · Paliperidone palmitate (Invega Sustenna)'s landscape